Evaluation of arginine deiminase treatment in melanoma xenografts using 18F-FLT PET

Molecular Imaging and Biology

Volumn 15, Issue 6, 2013, Pages 768-775

  Stelter, Lars ^a,b   Fuchs, Simon ^a   Jungbluth, Achim A ^b   Ritter, Gerd ^b   Longo, Valerie A ^b   Zanzonico, Pat ^b   Raschzok, Nathanael ^a   Sauer, Igor M ^a   Bomalaski, John S ^c   Larson, Steven M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Polaris Group   (United States)

Author keywords

Arginine deiminase; FLT PET; Melanoma xenograft; Response evaluation

Indexed keywords

3' FLUOROTHYMIDINE F 18; ARGININE DEIMINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; THYMIDINE KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG METABOLISM; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; METABOLIC REGULATION; MOLECULAR BIOLOGY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; HYDROLASES; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MELANOMA; MICE; SIGNAL TRANSDUCTION; THYMIDINE KINASE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890507814     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0655-6     Document Type: Article

References (39)

1. Izzo F, Marra P, Beneduce G et al (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22:1815-1822
2. Ascierto PA, Scala S, Castello G et al (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23:7660-7668
3. Glazer ES, Piccirillo M, Albino V et al (2010) Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28:2220-6
4. Feun LG, Marini A, Walker G et al (2012) Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 106:1481-5
5. Dillon BJ, Prieto VG, Curley SA et al (2004) Incidence and distribution of argininosuccinate synthetase deficiency in human cancers. Cancer 100:826-33
6. Kim RH, Coates JM, Bowles TL et al (2009) Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69:700-8
7. Kelly MP, Junbluth AA, Wu BW et al (2012) Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 106:324-32
8. Kobayashi E, Masuda M, Nakayama R et al (2010) Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 9:535-44
9. 18F-FDG as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med 47:901-3
10. 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med 53:281-6
11. Ott PA, Carvajal RD, Pandit-Taskar N et al (2012) Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 31(2):425-34. doi: 10.1007/s10637-012-9862-2
12. Rasey JS, Grierson JR, Wiens LW et al (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43:1210-17
13. Been LB, Suurmeijer AJH, Cobben DCP et al (2004) [18-F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Biol 31:1659-1672
14. Liu W, Zhou Y, Reske SN, Shen C (2008) PTEN Mutation: many birds with one stone in tumorigenesis. anticancer Res 28:3613-3620
15. 18F] fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma. Cancer 118:3135-44
16. Savaraj N, You M, Wu C et al (2010) Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 10:405-412
17. Syed N, Langer J, Janczar K et al (2013) Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis 4:e458
18. Delage B, Luong P, Maharaj L et al (2012) Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 3:e342
19. You M, Savaraj N, Wangpaichitr M et al (2010) The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Com 394:760-76
20. Lucignani G, Larson SM (2010) Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours. Eur J Nucl Med Mol Imaging 37:1032-8
21. Larson SM, Robbins R (2002) Positron emission tomography in thyroid cancer management. Semin Roentgenol 37:169-74
22. Lu SJ, Gnanasegaran G, Buscombe J, Navalkissoor S (2013) Single photon emission computed tomography/computed tomography in the evaluation of neurendocrine tumours: a review of the literature. Nucl Med Commun 34:98-107
23. Stelter L, Evans MJ, Junbluth AA et al (2013) Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging 12:67-73
24. Szlosarek PW, Luong P, Phillips MM et al (2013) Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 31:1-3
25. Hoshikawa H, Nishiyama Y, Kishino T et al (2011) Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell cancers. Mol Img Biol 13:172.7
26. Fatema CN, Zhao S, Zhao Y et al (2013) Monitoring tumor proliferation response to radiotherapy using (18)F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67. Ann Nucl Med 27(4):355-62. doi: 10.1007/s12149-013-0693-9
27. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263:8350-8358
28. Wang H, He Q, Skog S, Eriksson S, Tribukait B (2001) Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Pathol 23:11-19
29. De Saint-Hubert M, Brepoels L, Devos E et al (2012) Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition. Am J Nucl Med Mol Img 1:110-121
30. Feun L, Savaraj N (2006) Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 15:815-822
31. Mayo LD, Dixon DB, Durden DL et al (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-9
32. Schwartz JL, Tamura Y, Jordan R et al (2004) Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy- 3′fluorothymidine uptake. Nucl Med Biol 31:419-423
33. Freeman DJ, Li AG, Wei G et al (2003) PTEN tumor suppressor regulates p53 protein levels and activity through phostphatase-dependant and -independent mechanisms. Cancer Cell 3:117-30
34. Cui X, Witalison EE, Chumanevich AP et al (2013) The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition cause a p53-dependent cell cycle arrest. PLoS One 8:e53791
35. Paproski RJ, Wuest M, Jans HS et al (2010) Biodistribution and uptake of 3′deoxy-3′-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med 51:1447-55
36. Plotnik DA, McLaughlin LJ, Chan J et al (2011) The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3′-fluoro-3′-deoxythymidine in human B-lymphoblast cells. Nucl Med Biol 38:979-86
37. Plotnik DA, McLaughlin LJ, Krohn KA, Schwartz JL (2012) The effects of 5-fluoruracil treatment on 3′-fluoro-3′deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells. Nucl Med Biol 39:970-976
38. Höglund J, Shirvan A, Antoni G et al (2011) 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 52:720-5
39. Sobrio F, Médoc M, Martial L et al (2013) Automated radiosynthesis of [(18)F]ML-10, a PET radiotracer dedicated to apoptosis imaging, on a TRACERLab FX-FN module. Mol Imaging Biol 15:12-8